AHCO:NSD-Adapthealth Corp (USD)

COMMON STOCK | Medical Devices | NSD

Last Closing Price

USD 18.51

Change

-0.23 (-1.23)%

Market Cap

USD 2.52B

Volume

0.76M

Avg Analyst Target

USD 26.80 (+44.79%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

AHCO Stock Forecast & Price:
Based on the Adapthealth Corp stock forecasts from 7 analysts, the average analyst target price for Adapthealth Corp is USD 26.80 over the next 12 months. Adapthealth Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adapthealth Corp is Bullish , which is based on 9 positive signals and 3 negative signals. At the last closing, Adapthealth Corp’s stock price was USD 18.51. Adapthealth Corp’s stock price has changed by +3.29% over the past week, +3.47% over the past month and -33.61% over the last year.

About Adapthealth Corp (AHCO:NSD)

AdaptHealth Corp., together with its subsidiaries, provides home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to indivi ...Read More

Company Website : https://adapthealth.com

Address : 220 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Employees : 10,700

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 0.57

52 Week High : 28.75

Short Ratio : 4.70

52 Week Low : 11.40

Shorted Shares : 5,775,472

200 Day Moving Average : 19.59

Shorted Shares Previous Month : 7,520,112

50 Day Moving Average : 16.21

Shares Held By Insiders : 24.18%

Short Percentage : 7.66%

Shares Held by Institutions : 72.37%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-06-29 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DXCM DexCom Inc

+0.75 (+1.00%)

 USD29.32B 152.76 69.64
ALGN Align Technology Inc

+0.23 (+0.10%)

 USD19.06B 27.23 17.74
PODD Insulet Corporation

-4.27 (-1.89%)

 USD15.69B 354.01 91.62
LVGO Livongo Health, Inc

N/A

 USD14.20B N/A N/A
ABMD ABIOMED Inc

+7.41 (+2.97%)

 USD11.35B 85.59 38.10
BRKR Bruker Corporation

+0.40 (+0.64%)

 USD9.53B 34.50 18.45
SWAV Shockwave Medical Inc

-1.17 (-0.60%)

 USD7.08B 242.27 160.00
IART Integra LifeSciences Holdings

+1.39 (+2.55%)

 USD4.57B 29.88 16.49
TNDM Tandem Diabetes Care Inc

-0.15 (-0.25%)

 USD3.93B 691.24 150.78
WMGI Wright Medical Group N.V

N/A

 USD3.90B N/A 50.67

ETFs Containing AHCO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -24.33% 74% C 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.33% 74% C 48% F
Trailing 12 Months  
Capital Gain -32.47% 69% D+ 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -32.47% 69% D+ 46% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 24.54% 57% F 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.54% 57% F 79% C+
Risk Return Profile  
Volatility (Standard Deviation) 77.17% 36% F 18% F
Risk Adjusted Return 31.80% 55% F 63% D
Market Capitalization 2.52B 88% B+ 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.78 54% F 36% F
Price/Book Ratio 1.19 76% C 65% D
Price / Cash Flow Ratio 9.13 29% F 29% F
EV/EBITDA 7.54 58% F 55% F
Management Effectiveness  
Return on Equity 10.43% 91% A- 68% D+
Return on Invested Capital 7.05% 84% B 67% D+
Return on Assets 3.67% 85% B 75% C
Debt to Equity Ratio 105.65% 28% F 21% F
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.70 39% F 33% F
Short Percent 7.66% 23% F 24% F
Beta 0.57 85% B 82% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

New Post

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.